Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis

American Journal of Medicine

Volumn 123, Issue 4, 2010, Pages 350-357

  Kimball, Alexa Boer ^a   Guerin, Annie ^b   Latremouille Viau, Dominick ^b   Yu, Andrew P ^b   Gupta, Shiraz ^c   Bao, Yanjun ^c   Mulani, Parvez ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ANALYSIS GROUP   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Coronary heart disease; Psoriasis; Stroke

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; ATTRIBUTABLE RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; STROKE;

CORONARY DISEASE; HUMANS; PSORIASIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; TIME FACTORS;

EID: 77950106199     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.08.022     Document Type: Article

References (47)

1. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
2. Schmitt J., and Ford D.E. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis-a structural equations modeling approach. Gen Hosp Psychiatry 29 (2007) 134-140
3. Fowler J.F., Duh M.S., Rovba L., et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 59 (2008) 772-780
4. McDonald C.J. Cardiovascular disease in psoriasis. J Invest Dermatol 92 (1989) 646-647
5. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
6. Pearce D.J., Morrison A.E., Higgins K.B., et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 16 (2005) 319-323
7. Cohen A.D., Sherf M., Vidavsky L., et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 216 (2008) 152-155
8. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6 (1997) 813-820
9. Helms C., Saccone N.L., Cao L., et al. Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118 (2005) 466-476
10. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 (2007) 1493-1499
11. Kremers H.M., McEvoy M.T., Dann F.J., and Gabriel S.E. Heart disease in psoriasis. J Am Acad Dermatol 57 (2007) 347-354
12. Wakkee M., Thio H.B., Prens E.P., et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190 (2007) 1-9
13. Gottlieb A.B., Chao C., and Dann F. Psoriasis comorbidities. J Dermatolog Treat 19 (2008) 5-21
14. Kaye J.A., Li L., and Jick S.S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008) 895-902
15. Wu Y., Mills D., and Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 7 (2008) 373-377
16. Gordon K.B., Langley R.G., Leonardi C., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
17. Shikiar R., Heffernan M., Langley R.G., et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 18 (2007) 25-31
18. Saurat J.H., Stingl G., Dubertret L., et al., CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008) 558-566
19. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008) 106-115
20. Haq I.U., Ramsay L.E., Yeo W.W., et al. Is the Framingham risk function valid for northern European populations?. A comparison of methods for estimating absolute coronary risk in high risk men. Heart 81 (1999) 40-46
21. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 97 (1998) 1837-1847
22. Linn S., Fulwood R., Carroll M., et al. Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II). Am J Public Health 81 (1991) 1038-1043
23. D'Agostino R.B., Wolf P.A., Belanger A.J., and Kannel W.B. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 25 (1994) 40-43
24. Nair D., Carrigan T.P., Curtin R.J., et al. Association of coronary atherosclerosis detected by multislice computed tomography and traditional risk-factor assessment. Am J Cardiol 102 (2008) 316-320
25. Gottlieb A.B., Dann F., and Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 7 (2008) 563-572
26. Grundy S.M., Greenland P., Herd A., et al. Cardiovascular and risk factor evaluation of healthy American adults. A statement for physicians by an Ad Hoc Committee appointed by the Steering Committee, American Heart Association. Circulation 75 (1987) 1340A-1362A
27. Gartside P.S., Wang P., and Glueck C.J. Prospective assessment of coronary heart disease risk factors: the NHANES I epidemiologic follow-up study (NHEFS) 16-year follow-up. J Am Coll Nutr 17 (1998) 263-269
28. World Health Organization. BMI classification (2008). http://www.who.int/bmi/index.jsp?introPage=intro_3.html Accessed November 7
29. Spratt K.A. Reducing the risk of coronary heart disease via lipid reduction. J Am Osteopath Assoc 104 Suppl 7 (2004) 9-13
30. Herron M.D., Hinckley M., Hoffman M.S., et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 141 (2005) 1527-1534
31. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
32. Ogden C.L., Carroll M.D., McDowell M.A., and Flegal K.M. Obesity Among Adults in the United States-No Change Since 2003-2004 (2007), National Center for Health Statistics, Hyattsville, MD NCHS data brief no 1
33. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
34. Maradit-Kremers H., Crowson C.S., Nicola P.J., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52 (2005) 402-411
35. Warrington K.J., Kent P.D., Frye R.L., et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 7 (2005) R984-R991
36. Malerba M., Gisondi P., Radaeli A., et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 155 (2006) 1165-1169
37. McEwan P., Williams J.E., Griffiths J.D., et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21 (2004) 318-323
38. Coleman R.L., Stevens R.J., Retnakaran R., and Holman R.R. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30 (2007) 1292-1293
39. Rosamond W., Flegal K., Furie K., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
40. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
41. Lloyd-Jones D., Adams R., Carnethon M., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-e181
42. Rosamond W.D., Folsom A.R., Chambless L.E., et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 30 (1999) 736-743
43. Centers for Disease Control and Prevention (CDC). Prevalence of disabilities and associated health conditions among adults--United States, 1999. MMWR Morb Mortal Wkly Rep 50 (2001) 120-125
44. Centers for Disease Control and Prevention (CDC). Outpatient rehabilitation among stroke survivors-21 States and the District of Columbia, 2005. MMWR Morb Mortal Wkly Rep 56 (2007) 504-507
45. Feldman S.R., Ravis S., Moran W.P., and Fleischer Jr. A.B. Patients seen in a dermatology clinic have unmet preventive health care needs. J Am Acad Dermatol 44 (2001) 706-709
46. Kimball A.B., Gladman D., Gelfand J.M., et al., National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 (2008) 1031-1042
47. Prodanovich S., Ma F., Taylor J.R., et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52 (2005) 262-267